Skip to the page

Data / Form D filings / Elion Therapeutics, Inc.

Elion Therapeutics, Inc.: Form D filing

Elion Therapeutics, Inc., a biotechnology company in New York, NY, filed a Form D with the SEC in 2024. The latest, on June 26, 2024, reports $25.4 million sold of a $83.8 million offering to 6 investors.

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

Company details from the filing

Address
C/O DEERFIELD MANAGEMENT COMPANY LP, 345 PARK AVENUE SOUTH, New York, NY, 10010
Phone
(212) 551-1600
Industry
Biotechnology
Entity type
Corporation
Incorporated in
Delaware
Revenue range
Decline to Disclose
Exemptions claimed
Rule 506(b)
SEC identifier (CIK)
2028346

Form D filings

FiledTypeOfferingSoldRemainingInvestorsFirst saleFiling
Jun 26, 2024New notice$83,835,000$25,436,790$58,398,2106Jun 11, 2024sec.gov

Executive officers and directors named in the filing

NameRoleNote in the filing
Jim FlynnDirector
Kieren MarrExecutive Officer, Director
Martin HeideckerDirector
Jonathan LeffDirector

Other biotechnology companies in New York that filed recently

Every Form D from the week of Jun 24, 2024 · All recent filings in New York · All recent Biotechnology filings

Read from SEC EDGAR. Amount sold is what Elion Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.